The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases.
Get full access to this article
View all access options for this article.
References
1.
CooneyMMNockCBokarJ. Phase I trial of pomalidomide given for patients with advanced solid tumors. Cancer Chemother Pharmacol.2012;70(5):755–761.
2.
HoffmanMKasserraCReyesJ. Absorption, metabolism and excretion of [14C]pomalidomide in humans following oral administration. Cancer Chemother Pharmacol.2013;71(2):489–501.
3.
ScheySAFieldsPBartlettJB. Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma. J Clin Oncol.2004;22(16):3269–3276.
TefferiAVerstovsekSBarosiG. Pomalidomide is active in the treatment of anemia associated with myelofibrosis. J Clin Oncol. 2009; 27(27):4563–4569.
6.
StreetlyMJGyertsonKDanielY. Alternate day pomalidomide retains anti-myeloma effect with reduced adverse events and evidence of in vivo immunomodulation. Br J Haematol. 2008;141(1):41–51.
7.
BegnaKHMesaRAPardananiA. A phase-2 trial of low-dose pomalidomide in myelofibrosis. Leukemia. 2011;25(2):301–304.
TalpazMCortesJEDeiningerMW. Phase I trial of AP24534 in patients with refractory chronic myeloid leukemia (CML) and hematologic malignancies [abstract 6511]. J Clin Oncol.2010;28(Suppl):15s. http://meetinglibrary.asco.org/print/578804. Accessed June 8, 2013.
CortesJEKimDWPinilla-IbarzJ. PACE: A pivotal phase II trial of ponatinib in patients with CML and Ph+ALL resistant or intolerant to dasatinib or nilotinib, or with the T315I mutation [abstract 6503]. J Clin Oncol.2012;30(Suppl). http://meetinglibrary.asco.org/content/97216-114. Accessed June 8, 2013.
MauroMJCortesJEKantarjianHM. Safety and durability of ponatinib in patients with Philadelphia chromosome-positive (Ph+) leukemia: Long-term follow-up of an ongoing phase I study [abstract 7063]. J Clin Oncol.2013;31(Suppl). http://meetinglibrary.asco.org/content/113973-132. Accessed June 8, 2013.
18.
TalpazMShahNPDeiningerMW. Ponatinib in patients with acute myeloid leukemia (AML): Preliminary findings from a phase I study in hematologic malignancies [abstract 6518]. J Clin Oncol.2011;29(Suppl). http://meetinglibrary.asco.org/content/81698-102. Accessed June 8, 2013.
